Chronic Gout – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Gout is a disorder of purine metabolism that causes hyperuricemia and generally refers to a form of arthritis. The first symptoms include intense pain in only one hallux joint in 90% of the cases. The elevated blood uric acid level in men (serum-urate level >7 mg/dl) and in women (serum-urate level >6) results in the formation of monosodium urate (MSU) crystals and deposition in joint bones and subcutaneous tissue. Hyperuricemia is not the only factor for gout. Other factors also implicated in gouts, such as age, gender, obesity, alcohol consumption, medication, comorbid disease, genetics, and purine diet. Hyperuricaemia and gout can be considered over four pathological stages development of hyperuricemia, deposition of monosodium urate crystals, the clinical presentation of gout flares due to an acute inflammatory response to deposited crystals, and clinical presentation of an advanced disease characterized by tophi.

·       The estimated prevalence of gout in U.S. adults is 3.9% (5.2% in males and 2.7 in females).

Thelansis’s “Chronic Gout Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Gout treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chronic Gout across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Gout Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chronic Gout – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033